KODIAK SCIENCES INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
KODIAK SCIENCES INC. (KOD) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $40.80 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-31
- KODIAK SCIENCES INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $40.80M, a 67.70% decline from fiscal 2024.
- KODIAK SCIENCES INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $126.30M, a 391.44% increase from fiscal 2023.
- KODIAK SCIENCES INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $25.70M, a 64.31% decline from fiscal 2022.
- KODIAK SCIENCES INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $72.00M, a 66.32% decline from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $40.80M 10-K · filed 2026-03-31 | |
| 2024-12-31 | $126.30M 10-K · filed 2026-03-31 | -$126.30M 10-K · filed 2025-03-27 |
| 2023-12-31 | $25.70M 10-K · filed 2025-03-27 | |
| 2022-12-31 | $72.00M 10-K · filed 2024-03-28 | -$72.00M 10-K · filed 2023-03-28 |
| 2021-12-31 | $213.80M 10-K · filed 2023-03-28 | |
| 2020-12-31 | $24.80M 10-K · filed 2023-03-28 | |
| 2019-12-31 | $15.90M 10-K · filed 2022-03-01 | |
| 2018-12-31 | $8.20M 10-K · filed 2021-03-01 | |
| 2017-12-31 | $4.80M 10-K · filed 2020-03-16 | |
| 2016-12-31 | $6.20M 10-K · filed 2019-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |